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Abstract
Background: Second-generation antipsychotic drugs have been reported to cause fewer incidences of
extrapyramidal side effects (EPSs) than typical antipsychotic drugs, but adverse events such as akathisia have been
observed even with atypical antipsychotic drugs. Although understanding of the pathophysiology of akathisia
remains limited, it seems that a complex interplay of several neurotransmitter systems might play a role in its
pathophysiology. The endoplasmic reticulum protein sigma-1 receptors are shown to regulate a number of
neurotransmitter systems in the brain.
Methods: We report on two cases in which monotherapy of the selective serotonin reuptake inhibitor and sigma-
1 receptor agonist fluvoxamine was effective in ameliorating the akathisia of patients with schizophrenia treated
with the antipsychotic drug aripiprazole.
Results: The global score on the Barnes Akathisia Scale in the two patients with schizophrenia treated with
aripiprazole decreased after fluvoxamine monotherapy.
Conclusion: Doctors may wish to consider fluvoxamine as an alternative approach in treating akathisia associated
with antipsychotic drugs such as aripiprazole.
Background
Second-generation antipsychotic drugs have been
reported to cause fewer incidences of extrapyramidal
side effects (EPSs) than typical antipsychotic drugs, but
adverse events such as akathisia have been observed
even with atypical antipsychotic drugs. Akathisia is one
of the most common and distressing EPSs of antipsy-
chotic drugs [1,2]. The development of akathisia can
adversely affect patients’ adherence to medication, and,
as a consequence, have a negative impact on long-term
treatment outcomes in patients with schizophrenia [3,4].
Although therapeutic drugs (for example, b-adrenergic
blockers, benzodiazepines, and anticholinergic drugs)
have been used in the treatment of akathisia, they show
only a moderate efficacy, and a substantial proportion of
patients fail to respond to treatment. In contrast, under-
standing of the pathophysiology of akathisia remains
limited. Given the clinical profile of akathisia, it seems
that a complex interplay of several neurotransmitter sys-
tems (for example, dopamine, acetylcholine, norepi-
nephrine, serotonin, g-aminobutyric acid (GABA), and
neuropeptides) underlies its complex pathophysiology
[1,2].
The endoplasmic reticulum protein sigma-1 receptors
play a key role in Ca
2+ signalling and cell survival, and
have been shown to regulate a number of neurotrans-
mitter systems in the central nervous system [5-8]. A
recent study identified the sigma-1 receptors as posses-
sing innate biological activity as a molecular chaperone,
activity that can be activated/inactivated by synthetic
compounds that bind to sigma-1 receptors [9,10].
Furthermore, sigma-1 receptors play important roles in
the Ca
2+ signalling and bioenergetics within the cell
[8-10]. The selective serotonin reuptake inhibitor (SSRI)
fluvoxamine is a very potent agonist on sigma-1 recep-
tors [11,12]. A study using a selective sigma-1 receptor
agonist [
11C]SA4503 and positron emission tomography
demonstrated that fluvoxamine binds to sigma-1 recep-
tors in living human brain at therapeutic doses,
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the mechanism of action of fluvoxamine [13].
Given the important role of sigma-1 receptors in the
regulation of neurotransmitter systems, we hypothesised
that fluvoxamine may be effective in the treatment of
akathisia associated with antipsychotic treatment. Aripi-
prazole is an antipsychotic drug that acts as a partial
a g o n i s ta td o p a m i n eD 2 receptors and serotonin 5-
hydroxytryptamine (5-HT)1A receptors, and an antago-
nist at 5-HT2A receptors. The Schizophrenia Trial of
Aripiprazole (STAR) study demonstrated a relatively
higher incidence of akathisia with aripiprazole compared
with placebo or other antipsychotic drugs (olanzapine,
quetiapine, or risperidone)[14]. Here, we report two
cases in which fluvoxamine was effective in treating ari-
piprazole-induced akathisia in patients with schizophre-
nia. Written informed consents were obtained from the
all patients in this case report.
Case reports
Case 1
The patient was a 24-year-old woman who met the
Diagnostic and Statistical Manual of Mental Disorders,
fourth edition (DSM-IV) criteria for schizophrenia.
Treatment with aripiprazol (12 mg) was initiated; 2 days
later, the patient complained of leg restlessness. Her glo-
bal score on the Barnes Akathisia Scale [15] was 3
(’moderate akathisia’). Fluvoxamine (50 mg, twice a day)
was administered. Substantial relief of akathisia was
noted on day 7 of fluvoxamine treatment. The dose of
aripiprazole was increased to 24 mg, since she still had
persecutory delusions and auditory hallucinations. Flu-
voxamine (50 mg) continued to be administered. After 3
weeks, she had no recurrence of the akathisia.
Case 2
The patient was a 41-year-old man who met the DSM-
IV criteria for schizophrenia. Because of quetiapine-
induced body weight gain, the antipsychotic drug was
changed to aripiprazole (6 mg). He showed signs of
akathisia after the dose of aripiprazole was increased to
12 mg. His global score on the Barnes Akathisia Scale
was 3. Administration of fluvoxamine (50 mg, twice a
day) rapidly improved the akathisia. He showed no signs
of akathisia after the dose of aripiprazole was increased
to 24 mg, his body weight decreased, and his mental sta-
tus was stable.
Discussion
To our knowledge, this is the first report demonstrating
that fluvoxamine is effective in the treatment of aripi-
prazole-induced akathisia of patients with schizophrenia.
Furthermore, we have experienced that fluvoxamine is
also effective in the treatment of other antipsychotic-
induced akathisia in patients with schizophrenia (data
not shown). Nonetheless, a randomised double-blind,
placebo-controlled study of fluvoxamine will be needed
to confirm its efficacy for the treatment of this syn-
drome. From these case studies, it is unclear whether
sigma-1 receptor agonism appears to be irrelevant to
the anti-akathitic action of fluvoxamine. In order to
confirm the role of sigma-1 receptors in the treatment
of akathisia, a randomised double-blind, placebo-con-
trolled study of the selective sigma-1 receptor agonist
(for example, cutamesine (SA4503)) in patients with
antipsychotic-induced akathisia would be also of
interest.
Akathisia is a neurological side effect of antipsychotic
medications, which are used to treat various psychiatric
disorders such as schizophrenia and bipolar disorders
[1,2,4]. It seems that akathisia is simply a dopamine D2
receptor blockade [1] although the precise mechanisms
underlying antipsychotic drugs-induced akathisia are
currently unclear. A number of neurotransmitter sys-
tems play a role in the complex pathophysiology of
akathisia [1,2]. At present, it is unclear whether sigma-1
receptor agonism is involved in the mechanisms of anti-
akathitic action of fluvoxamine. Considering the impor-
tant role of sigma-1 receptors in the regulation of a
number of neurotransmitter systems [5-8], it is likely
that indirect modulation of several neurotransmitter sys-
tems by sigma-1 receptor agonist may be involved in
the mechanisms of this drug although a further detailed
study will be necessary.
Conclusions
These two cases suggest that fluvoxamine may serve as
an alternative option in the treatment of antipsychotic-
induced akathisia in patients with schizophrenia. More
detailed randomised, double-blind studies of fluvoxa-
mine using larger samples should be performed to clar-
ify the role of sigma-1 receptors in the efficacy of
fluvoxamine for akathisia.
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